Frost & Sullivan Healthcare and Life Sciences experts are forecasting large disruptions, transformations and innovations to healthcare over the next several years, as the industry continues to evolve to more sustainable business models.
“Our interactive workshop is designed to help managers and CEOs understand key issues affecting the healthcare industry globally,” noted Sandeep Sinha, VP & Head, Healthcare and Life Sciences, Frost & Sullivan. “Advances in areas ranging from cancer immunotherapy products to blood testing, as well as the convergence of cutting-edge technology such as artificial intelligence and blockchain will help shape the healthcare industry into a much-anticipated, value-based care paradigm.”
With the aging population growing and demand for innovative medical technology growing at a rapid rate, this may catalyze opportunities to those looking to healthcare stocks.
Premier Health Group, Inc. (PHGRF) (PHGI) announced it has acquired all of the outstanding securities of Cloud Practice Inc. Cloud Practice’s Founders, consisting of several software developers and sales staff, will join the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers. The combined Premier and Cloud Practice ecosystem consists of over 3,000,000 patients.
“We are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records (EMR) system,” said Dr. Essam Hamza, CEO.
Premier Health is moving forward with a binding Letter of Intent to acquire two cash flow positive Metro Vancouver-based pharmacies with a combined annual revenue of over $6 million for the fiscal year and expects the acquisition to close in or about Q2 2019. The company also recently entered into a strategic partnership with China’s 360 Health, a healthcare subsidiary of 360 Security Technology. The two companies will implement an infrastructure whereby Premier will be providing second opinion services by connecting 360 Health’s patients in China with doctors in Canada both remotely and in person.
Titan Pharmaceuticals (TTNP) annouced it has successfully completed the transition of the Probuphine implant program from Braeburn Pharmaceuticals. Probuphine is a subdermal implant designed to deliver the opioid buprenorphine for treating opioid addiction. Titan reported a double-digit increase in total product shipments in the period following its assumption of responsibility for Probuphine sales in mid-June 2018 and that total shipments for the rest of the year also increased by over 20%.
“We are pleased that the initial stages of our relaunch have shown that the current market is highly receptive to our market segmentation strategy and core messaging,” said Titan’s Chief Commercial Officer, Dane Hallberg. “Along with the positive feedback we have received from both health care providers and their patients, the increase in product shipments suggests that our relaunch strategy is sound, and we look forward to updating investors as this initiative progresses.”
Titan completed a one-for-six reverse stock split of the company’s issued and outstanding shares of common stock, warrants and options last week. The reverse stock split is intended to increase the per share trading price of Titan’s shares of common stock to satisfy the $1 minimum bid price requirement for continued listing on Nasdaq, and to provide the company with available shares for future business and financing transactions, according to the company.
Geron Corporation (GERN) announced several key leadership decisions this month as it works to restructure their in-house development team to further support its plans to initiate a Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes by mid-year 2019. Geron announced the appointment of a new chief medical officer Dr. Aleksandra Rizo as well as Israel Gutierrez, M.D. as Vice President, Pharmacovigilance and Drug Safety as of earlier this month.
“As we transition to a late-stage development company, we are very pleased to welcome Dr. Aleksandra Rizo to Geron as Chief Medical Officer,” said John A. Scarlett, M.D., Chairman and CEO. “With Aleksandra’s prior experience as the clinical lead for the imetelstat program for more than three years at Janssen, as well as her wealth of leadership experience with other hematology-oncology development projects at both Janssen and Celgene, we believe she is uniquely suited to build and lead our clinical development team.”
Also, B. Riley has upgraded Geron to buy from a neutral rating, while raising its price target to $3.25 from $1.50. Geron’s average rating among analysts is a buy, with an average price target of $4.01.
This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.
Biotech Breakroom 